

ASX RELEASE

Board Changes – Paul Reid Appointed as Chairman

Wellington, NZ, 12th February 2019: Volpara Health Technologies ("Volpara"; ASX: VHT), a medical technology company whose AI imaging algorithms assist the early detection of breast cancer has today announced that current Director Paul Reid will take over as Chairman on 1st March 2019. Paul assumes the role from Roger Allen AM, and as foreshadowed at the time of Volpara's IPO in mid-2016 now means we have an Independent Chairman as per ASX best-practice guidelines.

Paul has considerable experience in governance and in high-growth, technology-based global companies emerging from New Zealand. He is currently Chairman of Figured Limited and Director of Comvita Limited, Christchurch International Airport and Pukeko Pictures LP.

In March last year, Paul was invited to join the Board with a view to becoming the Chairman as he is based in Wellington, Volpara's headquarters and the location of CEO Ralph Highnam. The Board believes it desirable for the Chair also to be based in Wellington to allow more quality time with the CEO and CFO.

Roger, who as the initial major investor in Volpara and then as Chair guided the company through its IPO and considerable early-stage growth, remains committed to the Company and will continue as a Director and significant Shareholder.

Kvahn Williamson

kwilliamson@we-buchan.com

WE Buchan

ENDS.

For further information, please contact:

Ralph Highnam, CEO Volpara Health Technologies ralph.highnam@volparasolutions.com

t: +64 21 149 0541 t: +61 3 9866 4722

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical applications for screening clinics provide feedback on breast density, compression, dose and quality, while its enterprise-wide software, VolparaEnterprise, provides role specific dashboards and wide-ranging benchmarking analytics to help clinics manage their business more efficiently.

VHT's technology and services have been used by customers and/or research projects in 36 countries and are supported by numerous patents, trademarks and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$40 million, including A\$20 million in April and May 2018. VHT is based in Wellington, New Zealand.

For more information, visit www.volparasolutions.com